NICE endorses Novartis' Entresto for some patients; Novo, IBM partner on digital diabetes platform;

@FiercePharma: NICE backs Astellas' Xtandi in pre-chemo patients, but J&J's Zytiga isn't so lucky. More | Follow @FiercePharma

@EricPFierce: #Sun #Pharma to launch generic Gleevec Feb. 1 but has said it won't be #manufacturing it at troubled Halol plant. Story | Follow @EricPFierce

@CarlyHFierce: Horizon shells out $510 million for access to gout med Kyrstexxa. News | Follow @CarlyHFierce

> The U.K.'s cost watchdogs have recommended NHS use of Novartis' ($NVS) Entresto for a subset of heart failure patients whose hearts are particularly poor at pumping blood. Release

> Novo Nordisk ($NVO) is teaming up with IBM to develop a digital platform for helping diabetics and their doctors manage their illness. Report

> Bayer says it has its eye on becoming a major oncology player. Report

Medical Device News

@FierceMedDev: Bloomberg: Embattled Theranos CEO continues to beat the 'transparency' drum. More | Follow @FierceMedDev

@EmilyWFierce: Novian Health reveals positive study results for breast cancer laser ablation device. Article | Follow @EmilyWFierce

> Medtronic, Samsung partner to develop neuromodulation implant apps for smart devices. Story

> Lab experts lash out at FDA move to beef up regulation of lab-developed tests. News

Biotech News

@FierceBiotech: AstraZeneca bets on the future of the 'secretome,' joining a $100M research effort. Story | Follow @FierceBiotech

@JohnCFierce: If @woodfordfunds didn't know about the questions circulating around $NWBO, you have to wonder if the DC vax thing came up for review. | Follow @JohnCFierce

@DamianFierce: A lot of culturally embarrassing quotes in this, but reporters calling 5% "an obscure black movement" is as damning as anything Shkreli says. | Follow @DamianFierce

> Wellcome invests $38M in another gene therapy startup, targeting hemophilia. News

> Otonomy wins FDA approval for a first-of-its-kind ear treatment. Article

And Finally... U.S. sales of antibiotics for use in food animals rose 23% between 2009 and 2014, federal regulators say, fueling antibiotic-resistant bacteria concerns. Report

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.